CA2128547A1 - Methode de separation de lipopolysaccharides bacteriens a partir de solutions renfermant des proteines - Google Patents
Methode de separation de lipopolysaccharides bacteriens a partir de solutions renfermant des proteinesInfo
- Publication number
- CA2128547A1 CA2128547A1 CA002128547A CA2128547A CA2128547A1 CA 2128547 A1 CA2128547 A1 CA 2128547A1 CA 002128547 A CA002128547 A CA 002128547A CA 2128547 A CA2128547 A CA 2128547A CA 2128547 A1 CA2128547 A1 CA 2128547A1
- Authority
- CA
- Canada
- Prior art keywords
- lps
- solution
- protein
- glass surface
- detergent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002158 endotoxin Substances 0.000 title claims abstract description 69
- 229920006008 lipopolysaccharide Polymers 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 30
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 14
- 238000000926 separation method Methods 0.000 title claims abstract description 6
- 239000011521 glass Substances 0.000 claims abstract description 38
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 37
- 239000003599 detergent Substances 0.000 claims description 26
- 239000002738 chelating agent Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 229940009976 deoxycholate Drugs 0.000 description 16
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 16
- 239000011324 bead Substances 0.000 description 9
- 102100035353 Cyclin-dependent kinase 2-associated protein 1 Human genes 0.000 description 8
- 239000000693 micelle Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- -1 Ca2+ Chemical class 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000002812 cholic acid derivative Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 108010072542 endotoxin binding proteins Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93202201.5 | 1993-07-26 | ||
| EP93202201 | 1993-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2128547A1 true CA2128547A1 (fr) | 1995-01-27 |
Family
ID=8214007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002128547A Abandoned CA2128547A1 (fr) | 1993-07-26 | 1994-07-21 | Methode de separation de lipopolysaccharides bacteriens a partir de solutions renfermant des proteines |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPH0769923A (fr) |
| CN (1) | CN1106021A (fr) |
| BR (1) | BR9402892A (fr) |
| CA (1) | CA2128547A1 (fr) |
| FI (1) | FI943467A (fr) |
| IL (1) | IL110418A0 (fr) |
| NO (1) | NO942733L (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102746414B (zh) * | 2012-07-20 | 2014-04-16 | 成都生物制品研究所有限责任公司 | 一种细菌脂多糖的沉降方法 |
| NL2013880B1 (en) * | 2014-11-26 | 2016-10-11 | Rousselot B V | Gelatin purification. |
-
1994
- 1994-07-21 BR BR9402892A patent/BR9402892A/pt not_active Application Discontinuation
- 1994-07-21 FI FI943467A patent/FI943467A/fi not_active Application Discontinuation
- 1994-07-21 CA CA002128547A patent/CA2128547A1/fr not_active Abandoned
- 1994-07-21 NO NO942733A patent/NO942733L/no unknown
- 1994-07-22 IL IL11041894A patent/IL110418A0/xx unknown
- 1994-07-22 JP JP6191236A patent/JPH0769923A/ja active Pending
- 1994-07-22 CN CN94108161.3A patent/CN1106021A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NO942733D0 (no) | 1994-07-21 |
| IL110418A0 (en) | 1994-10-21 |
| FI943467A0 (fi) | 1994-07-21 |
| JPH0769923A (ja) | 1995-03-14 |
| CN1106021A (zh) | 1995-08-02 |
| BR9402892A (pt) | 1995-04-11 |
| FI943467A (fi) | 1995-01-27 |
| NO942733L (no) | 1995-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4483922A (en) | Inactivation of enzymes | |
| US4314997A (en) | Purification of plasma protein products | |
| EP0203509B1 (fr) | Procédé pour la détermination quantitative de la protéine-C et une préparation activatrice pour sa réalisation | |
| DE3852568T2 (de) | Verfahren zur Bestimmung der Anwesenheit von Endotoxin in einer Probe. | |
| Stewart et al. | Surface Particles of Sarcoplasmic Reticulum Membranes: STRUCTURAL, FEATURES OF THE ADENOSINE TRIPHOSPHATASE | |
| Hirst | THE NATURE OF THE VIRUS RECEPTORS OF RED CELLS: I. Evidence on the Chemical Nature of the Virus Receptors of Red Cells and of the Existence of a Closely Analogous Substance in Normal Serum | |
| DE3280463T2 (de) | Blutgerinnende Enzymzubereitungen. | |
| EP0031955B1 (fr) | Procédé de purification ou cholestérol lipoprotéinique pour son utilisation comme réactif standard du cholestérol | |
| JP3055933B2 (ja) | 改良された安定な凝固対照 | |
| US5702882A (en) | Reagent for endotoxin-specific assay | |
| US4672045A (en) | Method for assaying antigen-antibody reactions and reagent thereof | |
| DE69327211T2 (de) | Reagens für endotoxinspezifischen Assay | |
| US4946775A (en) | Composition, kit and method for assaying heparin and a method for making the composition | |
| JP4426720B2 (ja) | ワクチンの菌体内毒素除去方法 | |
| US4695537A (en) | Particles sensitized with detergent-treated antigen for agglutination immunoassay | |
| CA2128547A1 (fr) | Methode de separation de lipopolysaccharides bacteriens a partir de solutions renfermant des proteines | |
| EP0640351A1 (fr) | Méthode de séparation de lipopolysaccharides bactériens de solutions de protéines | |
| Hryniewicz et al. | Nature of the interaction between M protein of Streptococcus pyogenes and fibrinogen | |
| Shurin et al. | Complement (C3)-activated phagocytosis by lung macrophages | |
| DE69129365T2 (de) | Testagens für endotoxin | |
| EP0379133A2 (fr) | Utilisation de cations divalents dans les tests immunochimiques | |
| Gee | [22] Molecular titration of components of the classical complement pathway | |
| JP2577930B2 (ja) | 抗ストレプトリジンｏの新規測定法 | |
| EP1520035A2 (fr) | Procede de detection de l'activite de la protease de clivage du facteur de von willebrand d'adamts-13 | |
| JPH10282105A (ja) | 血清アミロイドａ測定用キャリブレーターの製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |